Peter J Greasley
Overview
Explore the profile of Peter J Greasley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hallow K, Greasley P, Heerspink H, Yu H
Front Pharmacol
. 2024 Dec;
15:1332388.
PMID: 39664514
Introduction: Endothelin-1 (ET-1) regulates renal and vascular function, but the clinical utility of selective ET receptor antagonists has been limited due to associated fluid retention. The mechanisms underlying fluid retention...
2.
Mariani L, Trachtman H, Thompson A, Gillespie B, Denburg M, Diva U, et al.
Am J Kidney Dis
. 2024 Oct;
PMID: 39455047
Focal segmental glomerulosclerosis (FSGS) is a characteristic histopathological lesion that is indicative of underlying glomerular dysfunction. It is not a single disease entity but rather a heterogeneous disorder that is...
3.
Smeijer J, Wasehuus V, Dhaun N, Gorriz J, Soler M, Astrand M, et al.
J Am Soc Nephrol
. 2024 Oct;
35(10):1381-1390.
PMID: 39352861
No abstract available.
4.
Abraham G, Williams T, Maguire J, Greasley P, Ambery P, Davenport A
Nat Cardiovasc Res
. 2024 Aug;
2(11):972-990.
PMID: 39196099
The first endothelin (ET)-1 receptor antagonist was approved for clinical use over 20 years ago, but to date this class of compounds has been limited to treating pulmonary arterial hypertension,...
5.
Yu H, Greasley P, Lambers Heerspink H, Ambery P, Ahlstrom C, Hamren B, et al.
Br J Pharmacol
. 2024 Aug;
181(22):4693-4707.
PMID: 39159936
Background And Purpose: Endothelin-1 (ET-1) receptor A (ETA) antagonists reduce proteinuria and prevent renal outcomes in chronic kidney disease (CKD) patients, but their utility has been limited because of associated...
6.
Mercier A, Ueckert S, Sunnaker M, Hamren B, Ambery P, Greasley P, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(3):653-664.
PMID: 38961664
Getting the dose right is a key challenge in drug development; model-informed drug development (MIDD) provides powerful tools to shape dose strategies and inform decision making. In this tutorial, the...
7.
Karlsson C, Johnson L, Greasley P, Retterstol K, Hedberg J, Hall M, et al.
JAMA Surg
. 2024 Jul;
159(9):971-980.
PMID: 38959017
Importance: Roux-en-Y gastric bypass (RYGB) is associated with reduced cardiovascular (CV) risk factors, morbidity, and mortality. Whether these effects are specifically induced by the surgical procedure or the weight loss...
8.
Ambery P, Greasley P, Menzies R, Brynne L, Kulkarni S, Oscarsson J, et al.
Clin Sci (Lond)
. 2024 Jun;
138(11):687-697.
PMID: 38835256
Endothelin A and B receptors, together with sodium-glucose cotransporter-2 (SGLT-2) channels are important targets in improving endothelial function and intervention with inhibitors has been the subject of multiple mechanistic and...
9.
Williams T, Kuc R, Paterson A, Abraham G, Pullinger A, Maguire J, et al.
Biosci Rep
. 2024 May;
44(6).
PMID: 38747277
Methods: Immunocytochemistry localised SGLT-2, ETA and ETB receptors in sections of histologically normal kidney, left ventricle from patients undergoing heart transplantation or controls. Primary antisera were visualised using fluorescent microscopy....
10.
Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure
Marton A, Saffari S, Rauh M, Sun R, Nagel A, Linz P, et al.
J Am Coll Cardiol
. 2024 Apr;
83(15):1386-1398.
PMID: 38599715
Background: Sodium-glucose cotransporter 2 inhibitors are believed to improve cardiac outcomes due to their osmotic diuretic potential. Objectives: The goal of this study was to test the hypothesis that vasopressin-driven...